University of Sheffield's research team leads world's first trial of new heart attack drug treatment

Heart attack patients may benefit from a new rapid anticlotting medication that can be given as a single injection, according to a new UK research.

Researchers from the University of Sheffield led a study showing that a new drug "Selatogrel" has a very rapid onset of action in patients with heart disease and may have ideal qualities for heart attack treatment.

The research has shown that Selatogrel may provide an alternative treatment for patients during the early stages of a heart attack, the university said in a release.

Professor Rob Storey, the Cardiovascular Research Unit team at the University of Sheffield, and Sheffield Teaching Hospitals NHS Foundation Trust have led the first international study of Selatogrel in patients with heart artery disease.

Oral drugs currently in use can take hours to work, particularly in patients who require pain relief such as morphine for their heart attack but the study found Selatogrel may provide a solution to this.

Results from the Selatogrel .